Coalition submits formal comment on FDA Draft Guidance on “Presenting Risk Information in Prescription Drug and Medical Device Promotion”.
The coalition’s comment, which commends the draft’s many strong points, also criticizes what they believe is the FDA’s over complication of advertising and promotion.
Read the full comment
FDA Draft Guidance: Coalition Submits Formal Comment
Coalition submits formal comment on FDA Draft Guidance on “Presenting Risk Information in Prescription Drug and Medical Device Promotion”.
The coalition’s comment, which commends the draft’s many strong points, also criticizes what they believe is the FDA’s over complication of advertising and promotion.
Read the full comment
Related Posts
What Pharma Can Teach Every Marketer About Risk, Regulation and Trust
Summary, Analysis and Recommendations on the Administration’s Announcements to Limit Rx Ads
Fact Sheet on the Benefits of Healthcare Communication & Marketing